SSG Capital Advisors served as the investment banker to Navidea Biopharmaceuticals in the sale of substantially all assets to Cardinal Health. The sale was effectuated through a Chapter 11 Section 363 process in the U.S. Bankruptcy Court for the District of Delaware. The transaction closed in February 2026. SSG created a dynamic and competitive auction environment, and Cardinal Health emerged as the prevailing bidder for substantially all of the company’s assets. This acquisition preserves the significant work surrounding the company’s Improved API program.
Read the full article: SSG Advises Navidea Biopharmaceuticals in the Sale of Substantially All Assets to Cardinal Health //
Source: https://www.abfjournal.com/ssg-advises-navidea-biopharmaceuticals-in-the-sale-of-substantially-all-assets-to-cardinal-health/